HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?

Lexicon

Annual NHI Drug Price Revisions:
毎年改定

The Column

The Truth about Recruiters

Archives

MHLW Looking into Drug Maker Payments to PAFSC Members: Shiozaki(Apr.24)
Astellas Sees 59% Rise in FY2014 Operating Profit(Apr.24)
LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry(Apr.24)
Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups(Apr.24)
MHLW Orders Revision of Package Inserts for Plavix(Apr.24)

Most Read

1.
Sales Rep Survey - Part 1: Decreases in ...
2.
Baxter Files NDA for Advate Successor in...
2.
Merck KGaA, Pfizer Start Multinational P...
2.
Takeda Hooks Up with Prof. Yamanaka on i...
5.
Who Will Foot the Bill for Cost-Effectiv...

News Calendar